Small molecule · Inhibitor of IRAK4 · developed by Curis
Emavusertib is an orally bioavailable reversible inhibitor of IRAK4 kinase. It blocks IRAK4-mediated signaling and NF-kB pathway activation, reducing inflammatory cytokine expression and pro-survival factors. It is studied in relapsed or refractory hematologic malignancies, primary CNS lymphoma, myelodysplastic syndromes, and anemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05178342 | Phase 2 | Myelodysplastic Syndromes | Terminated | CRIS |
| NCT03328078 | Phase 1/2 | Relapsed Hematologic Malignancy | Recruiting | CRIS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Refractory Hematologic MalignancyRefractory Primary Central Nervous System LymphomaRelapsed Hematologic MalignancyRelapsed Primary Central Nervous System LymphomaAnemiaMyelodysplastic Syndromes
Updated Oct 3, 2026. Something wrong or missing? Report it on the CRIS page.
See CRIS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRIS catalysts and pipeline →